Katia N. Estrada-Medrano, Hematology Service, School of Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico Alejandro Rodríguez-Garza, Hematology Service, School of Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico Mario C. Salinas-Carmona, Department of Immunology, School of Medicine, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico David Gómez-Almaguer, Hematology Service, Facultad de Medicina, Hospital University “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico


The coronavirus disease pandemic is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection can result in mild-to-severe disease, although many asymptomatic infections are described. There are many types of vaccines with different characteristics, and many have reached Phase III of clinical trials. In this review, we included the main vaccines approved worldwide, including those approved in Mexico. Vaccine-induced immune thrombotic thrombocytopenia has been described, especially in adenovirus vector vaccines. There are specific concerns around vaccine safety and efficacy in special populations such as pregnant women and immunosuppressed individuals. Even though the evidence is scarce, vaccine application remains recommended in most cases. We concluded that the risks of adverse effects from the vaccines are minimal compared to the current risk of contracting the SARS-COV-2 infection. The benefit of applying the vaccines is greater than not applying them at all.



Keywords: Coronavirus disease. Vaccines. Vaccine development.